Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

NCT03864978 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

236

Enrollment

INDUSTRY

Sponsor class

Conditions

Papulopustular Rosacea

Interventions

DRUG: Rifaximin delayed release 400 mg tablet
DRUG: Placebo

Sponsor

Alfasigma S.p.A.